Faculty of Medicine, Department of Pharmacology, EPS Fattouma Bourguiba, University of Monastir, Monastir, Tunisia.
Contact Dermatitis. 2019 Jul;81(1):24-26. doi: 10.1111/cod.13225. Epub 2019 Mar 4.
Non-steroidal anti-inflammatory drugs constitute a main cause of fixed drug eruption (FDE). A few cases of piroxicam-induced FDE have been reported; however, the cross-reactivity among oxicams has rarely been evaluated.
To describe a series of patients with piroxicam-induced FDE, mostly confirmed by a positive patch test reaction, in whom cross-reactivity to meloxicam was assessed.
We included all cases of piroxicam-induced FDE diagnosed in the department of pharmacovigilance of Monastir. Patch tests for piroxicam and meloxicam were performed in the involved skin according to the European Network on Drug Allergy recommendations. Oral provocation tests (OPTs) were performed for patients with negative skin test results.
Seven patients were included in this study. FDE was multiple for five patients and solitary for two. Bullous eruption was noticed in two cases. Lesional patch tests for piroxicam gave positive results in six patients. To assess cross-reactivity with meloxicam, this was patch tested. The test gave a positive result in only one patient. OPTs with meloxicam gave positive results in two patients with negative patch test results.
Meloxicam is not a safe alternative for the treatment of piroxicam-induced FDE, and OPTs can be used to confirm tolerance before this drug is prescribed as a safer alternative.
非甾体抗炎药是固定型药物疹(FDE)的主要原因之一。已有少数吡罗昔康引起的 FDE 报告,但很少评估昔布类药物之间的交叉反应性。
描述一组由吡罗昔康引起的 FDE 患者,这些患者主要通过阳性斑贴试验反应得到确诊,并评估其对美洛昔康的交叉反应性。
我们纳入了在莫纳斯蒂尔药物监测部门诊断的所有由吡罗昔康引起的 FDE 病例。根据欧洲药物过敏网络的建议,在受累皮肤中进行吡罗昔康和美洛昔康斑贴试验。对皮肤试验结果为阴性的患者进行口服激发试验(OPT)。
本研究共纳入 7 例患者。5 例为多形性 FDE,2 例为孤立性 FDE。2 例出现水疱性皮疹。6 例患者的皮损斑贴试验对吡罗昔康呈阳性。为评估与美洛昔康的交叉反应性,对其进行了斑贴试验。只有 1 例患者的试验结果为阳性。对皮试结果为阴性的 2 例患者进行 OPT 试验,结果为阳性。
美洛昔康不是治疗吡罗昔康引起的 FDE 的安全替代药物,在开美洛昔康之前,可以使用 OPT 来确认患者是否耐受。